What Changed
- Pasithea Therapeutics Presents Positive Initial Phase 1/1b Data for PAS-004, Showing Substantial Reductions in Cutaneous Neurofibroma Size and Early Activity in Plexiform Neurofibromas at the 2026 European Neurofibromatosis Conference
- Coastlands Capital, a 10% owner, buys 1.67M shares in Pasithea Therapeutics (KTTA).
Price Move History
- Daily moves over 5%
- 53 252 sessions, November 20, 2025 to November 20, 2026
- Largest daily move
- +117.4% close of November 26, 2025
- 1-year change
- +15.3% closing prices, November 20, 2025 to November 20, 2026
- 1-month change
- +16.8% closing prices, October 20, 2026 to November 20, 2026
Company Description
Pasithea Therapeutics Corp. is a clinical-stage biotechnology company developing drug candidates for central nervous system disorders, RASopathies, MAPK pathway-driven tumors and other diseases. The company’s common stock trades on The Nasdaq Capital Market under the symbol KTTA, and its listed warrants trade under KTTAW. Pasithea is organized as a Delaware corporation and reports its principal executive office in Miami Beach, Florida.
The company’s current development focus is PAS-004, a next-generation macrocyclic MEK inhibitor. MEK inhibition targets signaling in the MAPK pathway, a biology area relevant to RASopathies and certain tumors. Pasithea describes PAS-004 as its lead therapeutic candidate and has positioned the program for neurofibromatosis type 1, including NF1-associated plexiform neurofibromas and cutaneous neurofibromas, as well as MAPK pathway-driven tumors and other diseases.
Lead program and disease focus
Pasithea’s PAS-004 program is centered on diseases where aberrant MAPK pathway signaling is a therapeutic target. The company has identified neurofibromatosis type 1, or NF1, as a principal indication area, with clinical development directed at NF1-associated plexiform neurofibromas and related manifestations. The company has also reported clinical development activity in advanced cancer and research activity related to amyotrophic lateral sclerosis, or ALS.
PAS-004 has received U.S. Food and Drug Administration regulatory designations for specific NF1 uses, including Orphan Drug Designation, Fast Track Designation and Rare Pediatric Disease Designation. These designations are part of the regulatory framework for developing therapies for serious, rare or pediatric diseases and are distinct from product approval. Pasithea remains a development-stage company, and its business model depends on research, clinical development, regulatory progress, financing activity and potential future commercialization or licensing outcomes.
Business model and operating structure
Pasithea operates as a biotechnology research and development company rather than as a commercial drug seller. Its recurring activities include preclinical research, clinical trial execution, regulatory communications, medical strategy, intellectual property development, financing transactions and corporate governance. The company’s reported business is focused on research and development of treatments for central nervous system disorders and other diseases, including RASopathies and certain cancers.
Like many clinical-stage biotechnology issuers, Pasithea funds its operations through capital markets activity and other financing sources while advancing its product candidates through clinical and regulatory pathways. Company disclosures also reference potential use of capital for ongoing research, clinical trials, development of biological and pharmaceutical technologies, licensing activities, acquisitions of complementary technologies or businesses and working capital.
Public-company profile
Pasithea is an emerging growth company under U.S. securities rules, according to its SEC filings. Its public-company disclosures cover its common stock and warrants, registration statements for securities offerings, governance matters, equity incentive plan approvals, executive appointments, Regulation FD communications, Nasdaq listing compliance matters, and risk factors associated with a clinical-stage biotechnology company. These disclosures frame Pasithea as a focused drug-development issuer whose value proposition is tied primarily to PAS-004 and related clinical, regulatory and financing developments.
Stock Performance
Pasithea Therapeutics (KTTA) closed at $0.4787 on November 20, 2026. Over the past 12 months, the price has gained 15.3%.
KTTA Metrics & Rankings
Price returns through November 20, 2026. Month and year figures include the first trading day. Ranking links may use different dates.
Latest News
Pasithea Therapeutics has 10 recent news articles. Of the recent coverage, 2 articles coincided with positive price movement and 8 with negative movement. Key topics include clinical trial. View all KTTA news →
SEC Filings
Pasithea Therapeutics has filed 10 recent SEC filings, including 4 Form SCHEDULE 13G/A, 3 Form 8-K, 1 Form 4, 1 Form 10-Q. The most recent filing was submitted on . SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all KTTA SEC filings →
Insider Radar
Insider buying activity at Pasithea Therapeutics over the past 90 days may reflect management confidence in the company's direction. Institutional investors and analysts often monitor insider purchases as a potential bullish indicator for the stock.
Financial Highlights
Pasithea Therapeutics reported operating income of -$20.9M in FY2025, and net income was -$20.4M. Diluted earnings per share stood at -$2.91. The company generated -$15.2M in operating cash flow. The current ratio was 11.35, measuring current assets divided by current liabilities.
Upcoming Events
Short Interest History
Short interest in Pasithea Therapeutics (KTTA) currently stands at 386.7 thousand shares, up 121.5% from the previous reporting period, representing 1.1% of the float. Since November 2025, short interest has decreased by 90.0%.
Days to Cover History
Days to cover for Pasithea Therapeutics (KTTA) currently stands at 1.0 days, down 35.9% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Across the settlements charted above, it has ranged from 1.0 to 2.9 days.
KTTA Company Profile & Sector Positioning
Pasithea Therapeutics (KTTA) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.
Investors comparing KTTA often look at related companies in the same sector, including LeonaBio, Inc. (LONA), Cocrystal Pharma, Inc. (COCP), Marker Therapeutics, Inc. (MRKR), Akari Therapeutics plc (AKTX), and Atossa Therapeutics, Inc. (ATOS). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate KTTA's relative position within its industry.